This study assessed the ability of recombinant human stem cell factor (rHuSCF) to mobilize stem cells in 44 patients who had failed a prior mobilization (CD34 + yield 0.5-1.9 Â 10 6 /kg BW) with filgrastim-alone or chemotherapyplus-filgrastim. The same mobilization regimen was used with the addition of rHuSCF. In the filgrastim-alone group (n ¼ 13), rHuSCF 20 lg/kg was started 3 days before filgrastim and continued for the duration of filgrastim. In the chemotherapy-plus-filgrastim group (n ¼ 31), rHuSCF 20 lg/kg/day plus filgrastim 5-10 lg/ kg/day were administered concurrently. Leukaphereses were continued to a maximum of four procedures or a target of X3 Â 10 6 CD34 + cells/kg. In both groups, CD34 + yield ( Â 10 6 /kg BW) of the study mobilization was higher than that of the prior mobilization (median: 2.42 vs 0.84 P ¼ 0.002 and 1.64 vs 0.99 P ¼ o0.001, respectively). In all 54 and 45% of patients in the filgrastim-alone group and chemotherapy-plus-filgrastim group, respectively, reached the threshold yield of 2 Â 10 6 / kg. The probability of a successful mobilization was the same in those with a CD34+ yield of 0.5-0.75 Â 10 6 /kg BW in the prior mobilization as in those with 0.76-1.99 Â 10 6 /kg BW. Downmodulation of c-kit expression and a lower percentage of Thy-1 positivity in the mobilized CD34 + cells were noted in the successful mobilizers compared with those in the poor mobilizers. This study shows that rhuSCF is effective in approximately half the patients who had failed a prior mobilization and allows them to proceed to transplant. It also points to the likely role of the SCF/c-kit ligand pair in mobilization.
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Bone Marrow Transplantation (2003) 31, 371-378. doi:10.1038/sj.bmt.1703860 Keywords: stem cell factor; stem cell mobilization Autologous stem cell transplantation has improved the clinical outcome of patients with chemosensitive, intermediate-grade non-Hodgkin's lymphoma or multiple myeloma. Mobilization of peripheral blood stem cells with filgrastim (r-metHuG-CSF) alone or with chemotherapy has been a major advance in improving the safety of transplantation by increasing the number of harvested hemopoietic stem cells. Despite this advance, some patients still fail to be mobilized and sufficient stem cells cannot be collected for transplantation. [1] [2] [3] [4] Endogenous stem cell factor (SCF) is the natural ligand for the proto-oncogene c-kit, a cell surface tyrosine kinase receptor, and is an early-acting synergistic cytokine. 5 Recombinant human stem cell factor (rHuSCF) is a 166-amino-acid nonglycosylated protein. By itself, rHuSCF has no direct mobilizing effect, but when combined with filgrastim and/or chemotherapy in nonrandomized studies, mobilization was enhanced by three to five-fold in both untreated and previously treated patients. [6] [7] [8] [9] [10] [11] However, enhancing the yield in patients who mobilized well does not guarantee that rHuSCF could mobilize in failed mobilizers. We have previously shown that remobilization using the same mobilization stimulus within 3 months produced progenitor yields not different from the initial mobilization. 12 While it is not ethical to repeat mobilization procedures in patients who have sufficient stem cells for transplantation, repeat mobilization studies may be done in patients who fail to mobilize sufficient cells for transplantation. 13 This design would avoid the confounding effect of interpatient differences and tests rHuSCF's efficacy by comparing the mobilization yield with and without rHuSCF in the same patient. Using a prior mobilization in the same patient as a historical control should provide a powerful way to study the efficacy of mobilization regimens.
In this multicenter study, we were interested to know if rHuSCF can enable the collection of sufficient stem cells for transplantation in patients who have failed conventional filgrastim-alone or chemotherapy-plus-filgrastim mobilization. Secondly, we investigated whether the downregulation of c-kit is involved in successful mobilization in these failed mobilizers, a phenomenon seen after mobilization with filgrastim-alone or with chemotherapy-plus-filgrastim.
Patients and methods

Patients and study design
The protocol was approved by the institutional ethics committees of the participating medical centers and all patients gave written informed consent before any studyrelated procedures were done. Patients were eligible for the study, if they had nonmyeloid malignancies suitable for treatment with high-dose therapy, were at least 18 years of age, had an absolute neutrophil count (ANC) between 1.5 and 10 Â 10 9 /l, and Eastern Cooperative Oncology Group status of p2. Patients were required to have X0.5 but o2 Â 10 6 CD34 + cells/kg collected within the past 3 months by at least three leukaphereses procedures after mobilization with a standard mobilization regimen of either filgrastim-alone or chemotherapy-plus-filgrastim. Whether the patient had filgrastim-alone or chemotherapy-plusfilgrastim in this prior mobilization was determined by the doctor treating the patient. However, patients received the same mobilization regimen plus rHuSCF during the study mobilization. Patients were excluded from enrolling in the study, if they had any history of seasonal or recurrent asthma within the preceding 10 years; any anaphylactic/ anaphylactoid-type event manifested by disseminated urticaria, laryngeal edema, and/or bronchospasm; or any history of angioedema or recurrent urticaria within the past 3 years. The study was performed between July and November 1999.
Rationale for study design
In this study patients had rHu-met-SCF added to their prior mobilization regimen. An active control was not possible for this study, as patients had already failed prior mobilization on filgrastim and/or chemotherapy alone thereby eliminating the possibility of a comparative arm. As such, the study was historically controlled by comparing patient's study yields with those from their previously failed mobilization.
Patients in the filgrastim-alone group received rHuSCF 20 mg/kg/day administered for 3 days before the commencement of filgrastim and continued daily until leukaphereses were completed. A maximum of 11 days of rHuSCF administration was allowed. Filgrastim 10 mg/kg/day was administered for 5-8 days with leukapheresis commencing on day 5 of filgrastim administration. Patients in the chemotherapy-plus-filgrastim group received rHuSCF 20 mg/kg/day plus filgrastim 5-10 mg/kg/day 24 h after the last day of mobilization chemotherapy, administered daily until leukaphereses were completed. Leukapheresis commenced when the white blood cell count was 42 Â 10 9 /l or peripheral blood CD34 + count was X5 Â 10 6 /l after the nadir. Four leukaphereses were scheduled for the study mobilization because previous studies have shown a more prolonged release of peripheral blood progenitors by rHuSCF and filgrastim.
14 A comparison of the study regimen with the previously failed mobilization might suggest a protocol requiring that patients undergo the identical number of leukaphereses that were administered under failed mobilization. However, leukapheresis yields from rHu-met-SCF mobilization have a tendency to maintain yield levels across leukapheresis as opposed to filgrastim-mobilized yields, which are more likely to decline progressively (data not shown). Hence, the study purposely compares a previously failed study yield on at least three leukaphereses with the protocol specification of a maximum of four leukaphereses. This avoids biasing against the potential of rHuSCF to produce meaningful yields in successive leukaphereses beyond what was achieved with filgrastim alone. The study design is shown in Figure 1 .
Leukaphereses were performed on a Fenwal CS3000 plus (Baxter, Deerfield, IL, USA) as described before 1, 12 and were continued until a maximum of four procedures were performed or until a target of X3 Â 10 6 CD34 + cells/kg was reached. Separate pilot tubes were cryopreserved for laboratory studies.
Patients were categorized into two groups by the amount of prior chemotherapy and/or radiation therapy received. Patients were classified as having had either extensive therapy (42 cycles of procarbazine HCI, mechlorethamine HCI, nitrosourea, including BCNU, melphalan; high-dose cytosine arabinoside totalling X7 g; X10 cycles of chemotherapy, or radiation to the mediastinum, abdomen, or pelvis, excluding spot radiation), or moderate/none (all other patients).
Study drugs
The rHuSCF used in this trial was produced using E. coli genetically engineered to express a methionine-terminated recombinant version of human SCF (ancestim; Stemgen s , Amgen Inc., Thousand Oaks, CA, USA). Filgrastim (Neupogen s , Amgen Inc., Thousand Oaks, CA, USA) is also an E. coli-genetically engineered recombinant protein.
Patients receiving rHuSCF received premedication with ranitidine, bismuth citrate, salbutamol sulfate, and cetirizine HCl starting 24 h before the first injection of rHuSCF and continuing every day of rHuSCF administration.
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CD34
+ and subset measurements
In the filgrastim-alone group, peripheral CD34 + counts were performed daily until completion of leukaphereses. In the chemotherapy-plus-filgrastim group, peripheral CD34 + counts were performed daily when the white blood cell count was 41 Â 10 9 /l and continued until the completion of leukaphereses.
The two-color, immunofluorescence-staining procedure and flow cytometric analysis have been previously described.
15 CD34 + cells were stained using HPCA2-PE (CD34) (Becton-Dickinson, Mountain View, CA, USA) and were enumerated by backgating for CD45 expression (KD56-FITC, Coulter, Miami, FL, USA) and low side scatter: CD34 + cell counts were performed on an aliquot of each day's peripheral blood harvest. CD34 + cell yield was calculated based on the patient's actual weight. The coexpression of the following antigens was studied on thawed cryopreserved cells on selected patients: stagespecific markers CD38 (Leu-17, Becton-Dickinson, Mountain View, CA, USA) and CD90 (Thy-1, PharMingen, San Diego, CA, USA); KDR (Sigma, St Louis, MO, USA), 16 multiple drug resistance, MDR-1 (Immunotech, Prague, Czech Republic), and stem cell factor receptor, CD117 (c-kit, PharMingen). The daily counts were performed in individual centers using similar methodology. The coexpression studies were performed in one central laboratory (Adelaide) over an 8-week period with the same batch of reagents and the same test calibrations. Downregulation was measured by a comparison of the peak fluorescence of the cell populations studied.
Statistical methods
CD34
+ cell yields from rHuSCF-supported mobilizations were compared with prior CD34 + mobilization yield using the exact distribution for permutation tests for paired samples (StatXact, Cytel Software, Cambridge, MA, USA). A threshold of 2.0 Â 10 6 CD34 + total (prior mobilization plus study mobilization) cell yield was taken as the most clinically relevant end point 4 to assess the influence of potential prognostic indicators and the ability to proceed to transplant.
Wilcoxon rank sum test or permutation tests were used for univariate comparison of continuous variables, and w 2 or Fisher's exact tests were used for univariate comparisons for categorical variables. For prognostic analysis, no more than a single variable was identified as associated with a threshold yield of 42.0 Â 10 6 CD34 + yield (sufficient yield for transplant); hence, multivariate analysis was not required.
Patients who did not undergo leukapheresis were retained in the analysis and assigned a CD34 + yield of zero. Patients who had more than the scheduled number of four leukaphereses were included in the analysis with only yields from the first four leukaphereses.
Results
Patients
Overall, 44 patients were enrolled (Table 1) . Of these, 13 subjects were previously mobilized with filgrastim-alone and 31 with chemotherapy-plus-filgrastim. The filgrastimalone group contained more extensively pretreated patients (Po0.01, Fisher's exact test) and the patients had a marginally higher baseline platelet count (P ¼ 0.049, Wilcoxon) than the chemotherapy-plus-filgrastim group. More patients in the chemotherapy-plus-filgrastim group had intermediate-grade non-Hodgkin's lymphoma compared with the filgrastim-only group, but fewer patients in the chemotherapy-plus-filgrastim group had a low-grade non-Hodgkin's lymphoma compared with patients in the filgrastim-only group, but the differences did not reach statistical significance. The CD34 + yields from the prior mobilization were similar in both groups.
All 44 enrolled patients underwent mobilization. One patient in each group underwent five leukaphereses and one patient mobilized with chemotherapy-plus-filgrastim underwent six leukaphereses as determined by the doctor treating the patient, but the extra leukaphereses did not help to achieve the threshold yield of 2 Â 10 6 CD34 + cells/ kg and were not included in the analysis. Two patients in the chemotherapy-plus-filgrastim group did not undergo leukapheresis: one was withdrawn because of a moderate allergic reaction; the other because peripheral blood CD34 + cell levels were insufficient to proceed to leukapheresis.
In the filgrastim-alone group, median CD34 + yield ( Â 10 6 /kg) from the study mobilization was significantly higher than that of the prior mobilization (median 2.42, range 0.37-4.26 vs median 0.84, range 0.56-1.04, Po0.002), and 7/13 (54%) reached the threshold dose of 2 Â 10 6 /kg. In the chemotherapy-plus-filgrastim group, CD34 + yield from the study mobilization was also significantly higher than that of the prior mobilization (median 1.64, range 0.0-5.52 vs median 0.99, range 0.50-1.96, Po0.001) (Figure 2) , and 14/31 (45%) reached the threshold dose of 2 Â 10 6 /kg. When the yield from the first mobilization (without rHuSCF) was added to the second (with rHuSCF), 85% of patients in the filgrastim-alone group had X2 Â 10 6
CD34
+ /kg and 74% of patients in the chemotherapyplus-filgrastim group reached the threshold. If a 'perprotocol' approach, that is, including only the yield from the first four leukaphereses, is used, 77 and 71% of the filgrastim-alone and chemotherapy-plus-filgrastim patients, respectively, reached the threshold.
In the subgroup of 14 patients whose prior yields were at the lower end of range (0.5-0.75 Â 10 6 CD34 + /kg), seven patients were mobilized successfully with the addition of rHuSCF. The percentage success rate is no different from those in the higher end of the range (0.76-1.99 Â 10 6 CD34 + /kg). Hence, for a minimum prior mobilization yield of 0.5 Â 10 6 CD34 + cells/kg, no clear threshold existed where a second rHuSCF-supported collection would not be successful.
A total of 23 patients underwent transplant, 16 in the chemotherapy-plus-filgrastim group and seven in the filgrastim-alone group. Other 10 patients went into remission and were not transplanted. These patients were still receiving chemotherapy at the time of writing. Of the transplanted patients, the median (range) time to recovery to 1.0 Â 10 9 neutrophils/l was 11 (4-19) days (n ¼ 21) and the median (range) time to recovery to 20 Â 10 9 platelets/l was 11 (7-120) days (n ¼ 20).
Prognostic factors
CD34
+ cells/kg (2.0 Â 10 6 ) was used as the threshold to define successful mobilization. 4 Using this threshold, the list of potential prognostic factors included prior mobilization CD34 + yield, disease type, extent of previous chemotherapy, cycles of radiotherapy, baseline hematology (platelet, neutrophil and white blood cell counts), sex, and age. Only the baseline platelet counts appeared different between patients who were successful and unsuccessful mobilizers, with medians of 200 Â 10 9 /l and 165 Â 10 9 /l, respectively (P ¼ 0.05). In the chemotherapy-plus-filgrastim group, 12/21 patients (57%) whose baseline platelet counts were 4200 Â 10 9 /l (Po0.02) did so and the CD34 + yield showed a significant correlation (Po0.001) to the baseline platelet counts. No significant association was seen for the filgrastim-alone group (r ¼ À0.07).
The levels of CD34 + cells in the good mobilizer group (median 0.47%) were significantly higher in the study mobilization compared with those of the prior mobilization (median 0.18%, P ¼ 0.002) and with the two mobilizations from the poor mobilizers (P ¼ 0.02 and 0.02, respectively). The levels of peripheral blood CD34 + cells in the poor mobilizer group showed no difference between the prior and the study mobilization (median 0.14 vs 0.14%, P ¼ 0.72).
The CD34 + cells from 18 patients who had sufficient pilot tubes for coexpression analysis were studied (Table 2) . Eight patients were from those whose yield from the rHuSCF-stimulated mobilization did not reach the 2 Â 10 6 / kg threshold (ie, poor mobilizers), and 10 were from those whose yield from the rHuSCF-stimulated mobilization reached the threshold (ie, good mobilizers).
As defined by CD38, MDR, KDR, Thy-1, and c-kit, the phenotypic subsets of CD34 + cells from the prior mobilization did not differ significantly between the poor and good mobilizers. Hence, the phenotype of CD34 + cells mobilized by filgrastim did not predict the result of the subsequent mobilization with rHuSCF added.
In the good mobilizers, the median percentage of CD34 + CD38 -cells (4.5%) in the study mobilization was lower than in the prior mobilization (7.0%), but the difference did not reach statistical significance (P ¼ 0.14). Fewer CD34 + cells coexpressed Thy-1 (median 11.3%) after mobilization with rHuSCF compared with the prior mobilization (24.9%; Po0.01), although the peak fluorescence did not differ. There was no difference in the percentage of CD34 + cells expressing MDR and KDR (Figure 3) .
When CD34 + cells from the study mobilization were studied, the Thy-1 positivity was higher in the poor mobilizer group compared with the good mobilizer group (median 34.9 vs 11.3%, P ¼ 0.005).
Measurement of downregulation of c-kit (Figure 4)
The phenotypes of the CD34 + populations from the first and second mobilizations were compared. In the poor Table 2 A comparison of the phenotypes of CD34+ cells harvested in the first and the second mobilizations with patients segregated according to the success of the second mobilization mobilizer group, no significant differences were observed; that is, rHuSCF did not induce any change in the CD34 + populations in this group (paired t-test). In contrast, in the good mobilizer group, the level c-kit expression was significantly lower on CD34 + cells from the second mobilization based on both percent positive (median 26.95 vs 1.44%, P ¼ 0.006) and peak fluorescence (22.4 vs 10.8, P ¼ 0.002). Thus, successful mobilization with rHuSCF was associated with strong downregulation of its receptor.
Discussion
This study shows that rHuSCF enhances peripheral blood stem cell mobilization in patients who had failed previously with either filgrastim-alone mobilization or chemotherapyplus-filgrastim mobilization; 54 and 45%, respectively, of patients in these two groups reached the threshold dose. When the yields of the prior and the study mobilizations were pooled, 77 and 71%, respectively, of patients in these two groups reached the 2 Â 10 6 CD34 + cells/kg threshold and were enabled to proceed to transplant. Furthermore, for a minimum prior mobilization yield of 0.5 Â 10 6 CD34 + cells/ kg, no clear threshold existed below which a second rHuSCFsupported mobilization would not be successful. This result is consistent with data that Azar et al 17 reported in abstract form, showing a 34% success rate in remobilization when rHuSCF was administered to 67 patients who failed a prior mobilization. rHuSCF has been shown to enhance filgrastim mobilization in nonrandomized studies, but this is the first report of a historically controlled study showing its efficacy in patients who had failed prior mobilization.
Our findings show that the addition of rHuSCF is an alternative to filgrastim dose escalation in remobilization. In a previous report we described that doubling the dose of filgrastim led to successful mobilization in six of 10 patients who had failed a prior mobilization with filgrastimplus-chemotherapy or filgrastim-only. 13 Further, patients enrolled in this filgrastim dose escalation program continued to show a 50% success rate (data not shown). While a comparison between these two options is still to be performed, rHuSCF may enhance mobilization using nonfilgrastim-dependent pathways and may be useful even in patients who fail mobilization with filgrastim.
Stem cell factor is the ligand for the receptor tyrosine kinase, c-kit, which has important signalling functions in early hemopoietic cells leading to cell survival, proliferation and differentiation. 18 Downregulation of c-kit has been one of the most consistent findings on mobilized CD34 + cells, 14, 15, 19 particularly on cells mobilized with rHuSCF, 14 and was shown to correlate with the yield of mobilization. 4, 15 This study supports that such a downregulation is part of successful mobilization with rHuSCF in patients with failed prior mobilization.
Binding of SCF downregulates cell surface c-kit by promoting dimerization, ubiquitination, internalization and degradation within minutes of binding. 20 In contrast, mobilization by rHuSCF and other agents takes several days, suggesting that additional mechanisms may be operative. c-kit mRNA is known to be downregulated by other cytokines, for example, granulocyte-macrophage colony-stimulating factor (GM-CSF) and transforming growth factor (TGF)b. 21, 22 Hence, modulation of cell surface c-kit may reflect the sequence of complex changes during the progress of mobilization.
The consistent association of reduced c-kit expression in CD34 + cells mobilized in different ways suggests that it may be central to the mechanism of mobilization. The importance of the SCF/c-kit ligand pair in mobilization is further indicated by a number of studies in animals. Cynshi et al 23 showed that Sl/Sl d mice that lack membraneassociated SCF, or W/W v mice that express only kinasedeficient c-kit on their stem cells, mobilize less well with granulocyte colony-stimulating factor (G-CSF). These studies suggest that triggering of c-kit signalling by membrane SCF on stromal cells is required for optimum G-CSF-induced mobilization.
Binding of c-kit on hemopoietic cells to membrane SCF on stromal cells can directly mediate adhesion. 24, 25 It is possible that rHuSCF could contribute to mobilization by competing with membrane SCF in this interaction. However, the time course of mobilization and the failure of various mobilization regimens in W/W v mice appear incompatible with this simple explanation. Furthermore, it has been suggested that cytokine-mediated progenitor cell proliferation and mobilization may be linked, 14, 26 in which case the known synergism between rHuSCF and filgrastim in proliferation could also enhance mobilization. It is also possible that SCF may interact with integrins another family of molecules involved in mobilization 27 but this is beyond the scope of the study.
In this study, the expression of marker of early ontogeny on CD 34 + cells did not show any distinctive difference between the failed and the successful mobilizations, except for a reduction in Thy-1 expression. The significance of such an isolated finding is uncertain. There was certainly no evidence of delayed or failed engraftment in patients transplanted with rHuSCF-mobilized cells.
In conclusion, rHuSCF seems capable of enhancing filgrastim-alone or chemotherapy-plus-filgrastim mobilizations even in patients who had failed prior mobilization. The mobilized cells are capable of rapid hemaopoietic reconstitution. Downregulation of c-kit on CD34 + cells is again noted in successful mobilization with the addition of rHuSCF in these patients with a failed prior mobilization. rHuSCF and c-kit downregulation may enhance mobilization via proliferation, integrin and other signalling pathways.
